12th Antibody Industrial Symposium 2024 June 20 - 21 2024 | Montpellier - France


schedule & speakers

Day 1

Thursday, June 22nd 2023


Registration and welcome coffee


Welcome Address



Design and Development of Antibody-Drug Conjugates: An Overview of the Progress in the Field and Perspectives on Future Prospects
John Lambert

John Lambert
Former Chief Scientific Officer, ImmunoGen, Inc. (retired 2018)
Honorary Professor, Queen's University Belfast, Northern Ireland
Consultant, Cambridge, Massachusetts, USA
John Lambert Consulting, USA

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali
USTTB Kassoum Kayentao

Prof. Kassoum Kayentao
University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali


Coffee Break - Exhibition Hall - B2B Meetings


Track What we have learnt from Non-Traditional Antibodies formats so far

Current and Next Generation ADCs
Pierre Fabre Alain Beck

Alain Beck
Senior Director
Biologics CMC & Developability, Pierre Fabre, France

Immune stimulant TLR7/8 agonist antibody drug conjugate for the treatment of CEACAM5-expressing tumors
SANOFI Alexandra Ferrier

Alexandra Ferrier
Senior Principal Scientist Group Head in Drug Conjugates Medicinal Chemistry
SANOFI, France

Identification and Therapeutic Application of Multispecific Antibodies
Merus Peter Lowe

Peter Lowe
Director Antibody Engineering
Merus, The Netherlands

Utilizing endocytosis as an ADC biomarker
Oslo University Hospital Anette Weyergang

Anette Weyergang
Senior scientist at the Institute for Cancer Research
Oslo University Hospital, Norway

BEACON® single cell technology and mRNA immunization: A unique combination for antibody discovery against GPCRs and difficult targets
MImAbs Manuel Pelé

Manuel Pelé
Project Manager
MImAbs, France

Writing the Future of Biologics with Synthetic DNA and High-throughput Antibody Production
Twist Bioscience Radhar Parmar

Radhar Parmar
Science and technology consultant, biologics - EMEA
Twist Bioscience

Track Cell Therapy: new approaches

EVOcells, immune effector cells derived from IPSc for allogeneic therapeutic appraoches in immuno-oncology
Evotec Michael Esquerré

Michael Esquerré
Vice-President Immuno-Oncology, Immuno-Oncology Therapeutic Area lead
Evotec, France

Life Saving stem Cell Therapy for inflammatory diseases
StemInov Danièle Bensoussan

Danièle Bensoussan
PU-PH - Head of Cellular Therapy Unit and Tissue Bank
Cord Blood Bank (UTCT)
Head of a Research Unit
CNRS, France


Lunch break - Exhibition Hall - B2B Meetings


Track Isolating Human Antibodies from the Human Repertoire

Antibodies from Resilient Individuals: A novel approach for Antibody Drug Discovery
Alchemab Therapeutics Ltd, UK Sandrine Legg

Sandrine Legg
Director of Phenotypic Screening, Research
Alchemab Therapeutics Ltd, UK

Monogenic autoimmunity as a source of antibodies with therapeutic and diagnostic potential
University of Tartu Kai Kisand

Kai Kisand
University of Tartu, Estonia

Speed up your therapeutics antibody research and production with no-wash immunoassay solutions
Revvity Marielle Mazille

Marielle Mazille
EMEAI Subject Matter Expert application Team Leader - Life Science Revvity

Comprehensive antigen-specific clonotype discovery in one week
10XGENOMICS Christophe Fleury

Christophe Fleury
Science & Technology Advisor 10XGENOMICS, France

Track Tackling Toxicity of CART Treatments

Joint Forces - Synergizing Microbiota-derived metabolites and Cellular Therapy
University Clinic Würzburg Maik Luu

Maik Luu
Junior Group Leader and Scientific Project Manager of T2EVOLVE
University Clinic Würzburg, Germany

Preclinical models to assess safety and efficacy of engineered T cells
Institut Cochin Emmanuel Donnadieu

Emmanuel Donnadieu
Group Leader
Institut Cochin, France


Coffee Break - Exhibition Hall - B2B Meetings


Pitch Session : Innovative Approaches and New trend Technologies

Development of a versatile intracellular antibody-based approach for targeted protein degradation
SANOFI Anaïs Cornebois

Anaïs Cornebois
PhD student
SANOFI & Centre en Cancérologie de Toulouse (CRCT)

Characterization and optimization of an antibody drug conjugate, Adcitmer, in the treatment of Merkel Cell Carcinoma
Université de Tours Aurelie Drouin

Aurelie Drouin
Research Engineer, ISP UMR1282
Université de Tours

The “Cure RA” project: Towards a targeted phagocytosis of ACPA+ B lymphocytes in Rheumatoid Arthritis
Université de Tours III Cyril Clavel

Cyril Clavel
Associate professor in Cell Biology
Infinity Inserm UMR1291 - Université Toulouse III

An automation platform for the production and characterization of patient derived monoclonal antibodies focusing on autoimmune neurological disorders
German Center for Neurodegenerative Diseases (DZNE) Dominik Stappert

Dominik Stappert
Scientist and Project Manager, CRFS-LAT
German Center for Neurodegenerative Diseases (DZNE)

A new platform for the high-throughput screening of soluble full-length IgG libraries
INRAE - Micalis Institute Esteban Lebrun

Esteban Lebrun
Post-doctoral researcher
INRAE - Micalis Institute

Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment-Drug Conjugates (FDCs)
Université de Tours Louis Jolivet

Louis Jolivet
PhD student
ISP UMR1282, Université de Tours

Extracellular vesicles: a powerful tool for membrane protein studies
CYTOBODX Vincent Delauzun

Vincent Delauzun
Research Scientist


POSTER Presentation - WINE & CHEESE


Cocktail Gala Dinner - Château Belmont

Day 2

Friday, June 23rd 2023


Welcome coffee



Sotatercept for the treatment of pulmonary arterial hypertension
Université Paris-Saclay Marc Humbert

Prof. Marc Humbert
Professor of Respiratory Medicine
Université Paris-Saclay, France

CAR T cell therapy in autoimmune disease
Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany Georg Schett

Prof. Dr. Georg Schett
Head of Department of Medicine 3 - Rheumatology and Immunology and Vice President Research
Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany


Coffee Break - Exhibition Hall - B2B Meetings


Track Biotherapeutics in Clinic: when the clinic is reshuffling the cards

Approved indications of CAR-T cells in Onco-hematology and immunomonitoring of patients receiving CAR-T cells
CHRU Nancy Marie-Thérèse Rubio

Marie-Thérèse Rubio
Professor in clinical immunology, stem cell transplantation, immunotherapy
CHRU Nancy, France

Counter-intuitive lessons from the clinical experience in chronic inflammatory diseases
CHU Bordeaux Thierry Schaeverbeke

Thierry Schaeverbeke
Head of the Rheumatology Department and Coordinator of Clinical Research
CHU Bordeaux, France

Novel insights into pathophysiology and further differences between AQP4-IgG- and MOG-IgG-associated diseases
University Hospital and Biomedical Center Ludwig-Maximilians University Munich Simone Mader

Simone Mader
Junior Group Leader
Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center Ludwig-Maximilians University Munich, Germany

Multi-armed oncolytic vectors for targeted modification of the tumor micro-environment
Transgene Eric Quèmeneur

Eric Quèmeneur
Executive VP, CSO
Transgene, France

Accelerating therapeutic development using advanced protein and antibody development platforms
Sino Biological Yu-Chih Lin

Yu-Chih Lin
Ph.D, Technical Specialist
Sino Biological

Track Overcoming Bioprocessing Challenges to go into Clinic

Session I

Strategies to overcome common challenges in the production and characterization of bi- and multi-specific antibodies
Ichno Sciences Sabrina Vollers

Sabrina Vollers
Senior Team Leader, Head of Functional and PK Bioanalytic
Ichno Sciences, Switzerland

From Discovery to Clinic: Overcoming Bioprocessing Challenges in Icosagen's Humanization of New Drug Candidates
ICOSAGEN Paule Hermet

Paule Hermet

Bioluminescent platform technology to drive antibody discovery and development
PROMEGA Jamison Grailer

Jamison Grailer
Sr. Research Scientist, Team Leader of the R&D cell-based bioassay development group

MAM studies on benchtop MS instruments to boost QbD process development and high-throughput testing of major CQAs in a regulated environment
Quality Assistance Géry Van Vyncht

Géry Van Vyncht
Scientific Director, R&D and Innovation
Quality Assistance, Belgium

SGS, your GMP partner for Process Biosafety & DS Characterisation
SGS Luc-Alain Savoy

Luc-Alain Savoy
Global Head of Biologics
SGS, Switzerland

Innovative Surface Chemistry for Reliable Antibody Characterization and Epitope Binning
Kimialys Claude Nogues

Claude Nogues
Scientific Director & Co-Founder


Lunch break - Exhibition Hall - B2B Meetings


Track MAbs Immunopharmacology, what's new?

A new COST Action: European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA)
University of Iceland Enotta George Kararigas

George Kararigas
University of Iceland, Iceland

Patient stratification/precision medicine & how to structure further clinical research in Europe for IMID with therapeutic antibodies
University of Nicosia Enotta Aliki Peletidi

Aliki Peletidi
Pharmacy Programme Coordinator, Lecturer in Applied Pharmacy Practice, Pharmacy Programme, Department of Health Sciences
University of Nicosia, Cyprus

Personalized dosing, the cost-effectiveness of Therapeutic Drug Monitoring of biologics
Medical University of Sofia Enotta Konstatin Tachkov

Konstatin Tachkov
Assistant Professor
Faculty of Pharmacy, Medical University of Sofia

Precision dosing of biopharmaceutical in inflammatory diseases
University of Tours David Ternant

David Ternant
Senior Lecturer
University of Tours, France

Track Overcoming Bioprocessing Challenges to go into Clinic

Session II

Innovative approaches to minimize the “QC tax” on Gene Therapy batch yield
UCB Pharma Gael Debauve

Gael Debauve
Head of Gene therapy CMC Analytics
UCB Pharma, Belgique

Leveraging Continuous Manufacturing to de-risk development from IND filing through to market supply
Just Evotec Biologics Nigel Shipston

Nigel Shipston
Senior Director - Business Development
Just Evotec Biologics

Plasmid engineering technology from Polyplus: to fast track your rmAbs Discovery
Polyplus Sylvain Julien

Sylvain Julien
Director of Research Genetic Engineering
Polyplus, France

Working smart: rapid characterization of bispecific antibodies and agglutination process with FIDA
FidaBio Marion Albasini

Marion Albasini
Business Developer
FidaBio, Denmark


CAR T cells : overview of a revolution

Mabdesign Elsa Kress

Elsa Kress
Head of Business Development
Mabdesign, France


Intellectual property and Biopharmaceuticals Round Table : Strategies to navigate an increasingly complex field

Dentons Loïc Lemercier

Loïc Lemercier
Associate and Head of IP & Technology
Dentons, France

REGIMBEAU Nicolas Bouquin

Nicolas Bouquin
Senior Associate, European & French Partner Attorney

Pierre Fabre Philippe Bessiere

Philippe Bessiere
Global Head of Patents
Pierre Fabre, France


Best Poster - Announcement of AIS2024


End of Congress

Organization contact
Ana Antunes
17 rue Crépet
69007 Lyon
+33 (0)6 26 33 63 21